{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 42,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "customer_journey",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a table to contrast what is included in the patient journey versus what is explicitly excluded (no preparation, no assisted therapy, no integration).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/30",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Dosing session monitors (DSMs) in the room provide no psychotherapeutic intervention\nDelivery protocol consistent with 2023 FDA Draft Guidance\nNo significant changes planned to treatment session delivery between Phase 2 and Phase 3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46f6acef-d062-4084-99cd-2775f546794a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.16,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Source: Study MMED008 internal study documents.\n2. FDA 2023 Draft Guidance: Psychedelic Drugs: Considerations for Clinical Investigations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c552429d-1e52-4e03-a45e-20e50671a6f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.94,
        "x": 0.03,
        "y": 0.38
      },
      "kind": "table",
      "text": "Pre-treatment, During treatment, Post-treatment columns with rows for Patient Journey in MMED008 and Not Part of Patient Journey in MMED008",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0e4890c-60ad-425e-9a8d-0b184d5e1484",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Treatment Paradigm: Standalone Drug Effects with No Psychotherapeutic Intervention",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f414c0cd-828b-4c59-9c15-42870953fe7a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "customer-journey-map",
      "slug": null,
      "matchId": "5ba0b32f-571e-45df-a219-ea4c9f202847",
      "evidence": "The table maps the patient experience across three stages: Pre-treatment, During treatment, and Post-treatment.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}